PENTRAXIN 3 AND C-REACTIVE PROTEIN IN SEVERE MENINGOCOCCAL DISEASE

The long pentraxin 3 (PTX3) is an important element of the innate immune system and has potential as a diagnostic tool in inflammatory conditions. We studied PTX3 in patients admitted to an intensive care unit with severe meningococcal disease and compared it with the short pentraxin C-reactive protein (CRP). Twenty-six patients with meningococcal disease were studied, 17 patients presented with meningococcal septic shock (shock group), and 9 patients presented with meningococcal meningitis or bacteremia (no-shock group). Pentraxin 3 and CRP were measured by enzyme-linked immunosorbent assay. High plasma concentrations of PTX3 (median, 579 &mgr;g/L) were seen at admission in patients with meningococcal disease. Concentrations were significantly higher in patients with shock compared with patients without shock (medians, 801 and 256 &mgr;g/L, respectively; P = 0.006). In contrast, CRP at admission was lower in the shock group as compared with the no-shock group (medians, 58 and 165 mg/L, respectively; P = 0.008). High PTX3 and low CRP concentration at admission discriminated between presence and absence of shock (area under the receiver operating characteristic curve, 0.85; P = 0.007 for PTX3 and area under the receiver operating characteristic curve, 0.84; P = 0.01 for CRP). PTX3 did not correlate with disease severity (pediatric risk of mortality) and days spent in the intensive care unit. PTX3 at admission and PTX3 peak concentration both showed a negative correlation with plasma fibrinogen concentrations. C-reactive protein concentration at admission correlated negatively with disease severity. In conclusion, PTX3 was an early indicator of shock in patients with severe meningococcal disease that followed a pattern of induction distinct from CRP.

[1]  T. Calandra,et al.  MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) IN MENINGOCOCCAL SEPTIC SHOCK AND EXPERIMENTAL HUMAN ENDOTOXEMIA , 2007, Shock.

[2]  B. Han,et al.  Long pentraxin 3 in pulmonary infection and acute lung injury. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[3]  Barbara Bottazzi,et al.  Pentraxins in Innate Immunity: From C-Reactive Protein to the Long Pentraxin PTX3 , 2007, Journal of Clinical Immunology.

[4]  C. Garlanda,et al.  Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells: stimulation by IL‐10 and inhibition by IFN‐γ , 2006, Journal of leukocyte biology.

[5]  P. Pickkers,et al.  VASCULAR ENDOTHELIAL GROWTH FACTOR IS INCREASED DURING THE FIRST 48 HOURS OF HUMAN SEPTIC SHOCK AND CORRELATES WITH VASCULAR PERMEABILITY , 2005, Shock.

[6]  A. Mantovani,et al.  Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections , 2005, Journal of medical virology.

[7]  A. Agrawal CRP after 2004. , 2005, Molecular immunology.

[8]  Pascale Jeannin,et al.  Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. , 2005, Immunity.

[9]  P. Brandtzaeg,et al.  Chemokine patterns in meningococcal disease. , 2005, The Journal of infectious diseases.

[10]  J. G. van der Hoeven,et al.  Microvascular permeability during experimental human endotoxemia: an open intervention study , 2005 .

[11]  M. Baker,et al.  Fever in the new millennium: a review of recent studies of markers of serious bacterial infection in febrile children , 2005, Current opinion in pediatrics.

[12]  C. Garlanda,et al.  Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. , 2005, Annual review of immunology.

[13]  J. Casado‐flores,et al.  Prognostic utility of the semi-quantitative procalcitonin test, neutrophil count and C-reactive protein in meningococcal infection in children , 2005, European Journal of Pediatrics.

[14]  A. Mantovani,et al.  The long pentraxin PTX3 up‐regulates tissue factor in activated monocytes: another link between inflammation and clotting activation , 2004, Journal of leukocyte biology.

[15]  B. Jilma,et al.  Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia , 2004, Critical care medicine.

[16]  S. Calvano,et al.  Effects of Drotrecogin Alfa (Activated) in Human Endotoxemia , 2004, Shock.

[17]  D. J. Unsworth,et al.  The immunopathogenesis of meningococcal disease , 2003, Journal of clinical pathology.

[18]  W. Hop,et al.  Procalcitonin as a prognostic marker in meningococcal disease , 2002, Intensive Care Medicine.

[19]  A. Mantovani,et al.  Long Pentraxin PTX3 Upregulates Tissue Factor Expression in Human Endothelial Cells: A Novel Link Between Vascular Inflammation and Clotting Activation , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[20]  A. Mantovani,et al.  PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. , 2001, Arthritis and rheumatism.

[21]  J. Volanakis,et al.  Human C-reactive protein: expression, structure, and function. , 2001, Molecular immunology.

[22]  V. Torri,et al.  Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients , 2001, Critical care medicine.

[23]  G Olivetti,et al.  PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. , 2000, Circulation.

[24]  A. J. van Vught,et al.  Pediatric risk of mortality (PRISM) score in meningococcal disease , 2000, European Journal of Pediatrics.

[25]  J. V. D. van der Meer,et al.  Update on meningococcal disease with emphasis on pathogenesis and clinical management. , 2000, Clinical microbiology reviews.

[26]  R. Malley,et al.  Clinical and hematologic features do not reliably identify children with unsuspected meningococcal disease. , 1999, Pediatrics.

[27]  J. V. D. Meer,et al.  Acute meningokokkeninfecties: lage C-reactief proteine (CRP)-concentratie in het serum bij opname wijst op fulminant beloop , 1998 .

[28]  Francesco Tedesco,et al.  Multimer Formation and Ligand Recognition by the Long Pentraxin PTX3 , 1997, The Journal of Biological Chemistry.

[29]  A. Sica,et al.  Characterization of the Promoter for the Human Long Pentraxin PTX3 , 1997, The Journal of Biological Chemistry.

[30]  T. Blundell,et al.  Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. , 1996, Blood.

[31]  R. Sauerwein,et al.  Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. , 1995, The Journal of infectious diseases.

[32]  J. Robotham,et al.  The acute-phase response. , 1995, New horizons.

[33]  J. Vilček,et al.  Relationship of TSG-14 protein to the pentraxin family of major acute phase proteins. , 1994, Journal of immunology.

[34]  A. Mantovani,et al.  Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. , 1994, Blood.

[35]  A. Whitehead,et al.  The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. , 1994, Immunology today.

[36]  J. Sills,et al.  Variation in serum C‐reactive protein across the clinical spectrum of meningococcal disease , 1993, Acta paediatrica.

[37]  P. Brandtzaeg,et al.  Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. , 1989, The Journal of infectious diseases.

[38]  U. Ruttimann,et al.  Pediatric risk of mortality (PRISM) score. , 1988, Critical care medicine.

[39]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[40]  A. Forrest,et al.  Letter: Procaine and malignant hyperthermia. , 1974, Lancet.